Community-Acquired Pneumonia Antibiotic Treatment
For otherwise healthy adults with community-acquired pneumonia managed as outpatients, treat with amoxicillin 1 g every 8 hours or doxycycline 100 mg twice daily for a minimum of 5 days. 1
Treatment Algorithm by Setting
Outpatient Treatment (No Comorbidities)
First-line options:
- Amoxicillin 1 g every 8 hours (strong recommendation based on proven efficacy for inpatient CAP and excellent safety profile) 1
- Doxycycline 100 mg twice daily (consider 200 mg first dose for rapid serum levels) 1
For patients with comorbidities (COPD, diabetes, heart/liver/renal disease, malignancy, or recent antibiotic use within 3 months):
- Respiratory fluoroquinolone (levofloxacin 750 mg daily, moxifloxacin 400 mg daily, or gemifloxacin 320 mg daily) 1, 2
- OR β-lactam plus macrolide combination:
Hospitalized Patients (Non-ICU)
Standard regimen:
- β-lactam (ceftriaxone 1 g daily OR cefotaxime 1 g every 8 hours) PLUS macrolide (azithromycin or clarithromycin) 2
- OR respiratory fluoroquinolone monotherapy (levofloxacin or moxifloxacin) 2
The combination of β-lactam plus macrolide is strongly recommended with level I evidence, providing coverage for both typical bacteria (especially Streptococcus pneumoniae) and atypical pathogens (Mycoplasma, Chlamydophila, Legionella) 2.
Severe CAP (ICU Admission)
Mandatory combination therapy:
- β-lactam (ceftriaxone, cefotaxime, or ampicillin-sulbactam) PLUS either:
Special circumstances requiring modified coverage:
For Pseudomonas risk factors (structural lung disease, recent hospitalization, recent broad-spectrum antibiotics):
- Antipseudomonal β-lactam (piperacillin-tazobactam, cefepime, imipenem, or meropenem) PLUS
- Ciprofloxacin or levofloxacin 750 mg
- OR antipseudomonal β-lactam PLUS aminoglycoside PLUS azithromycin 2
For MRSA risk factors (prior MRSA infection, IV drug use, recent influenza):
- Add vancomycin or linezolid to above regimens 2
Critical Management Points
Duration of Treatment
Treat for minimum 5 days and ensure patient is afebrile for 48-72 hours with no more than one CAP-associated sign of clinical instability before stopping 2. Recent evidence supports 3-day treatment for patients achieving clinical stability by day 3, particularly in younger patients with fewer comorbidities 3, 4.
IV to Oral Switch
Switch from IV to oral therapy when the patient is:
- Hemodynamically stable
- Clinically improving
- Able to ingest medications
- Has functioning GI tract
Do not observe inpatients on oral therapy unnecessarily - discharge when clinically stable 2.
Timing of First Dose
Administer first antibiotic dose in the emergency department before admission for hospitalized patients 2.
Common Pitfalls to Avoid
Macrolide monotherapy is no longer recommended due to increasing pneumococcal resistance (>25% in many regions) 2, 5
Do not use first-generation cephalosporins or trimethoprim-sulfamethoxazole - inadequate activity against resistant S. pneumoniae 6
Assess clinical response at 48-72 hours - lack of improvement warrants investigation for complications, resistant organisms, or alternative diagnoses 2
For penicillin-allergic patients: Use respiratory fluoroquinolone monotherapy 2
Avoid fluoroquinolones in patients with:
- History of tendon disorders
- Cardiac arrhythmias (especially with macrolides)
- Recent C. difficile infection However, these concerns are outweighed by mortality benefit in severe CAP 1
Pathogen-Specific Considerations
Once a specific pathogen is identified through reliable microbiological methods, narrow therapy to pathogen-directed treatment 2. S. pneumoniae remains the most common and lethal pathogen, accounting for two-thirds of bacteremic pneumonia cases 5.
For Legionella pneumonia, extend treatment to 21 days and consider adding rifampicin in severe cases 7, 8.